Cargando…

The pharmacokinetics of levobupivacaine 0.5% after infraorbital or inferior alveolar block in anesthetized dogs

INTRODUCTION: Data are lacking on the pharmacokinetic profile and safety of levobupivacaine (LB) used for regional anesthesia of the maxilla and mandibles in dogs. METHODS: Infraorbital block (n = 10), inferior alveolar block (n = 10) or both infraorbital and inferior alveolar blocks (n = 10) were a...

Descripción completa

Detalles Bibliográficos
Autores principales: Pavlica, Matic, Kržan, Mojca, Nemec, Ana, Kosjek, Tina, Baš, Anže, Seliškar, Alenka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794753/
https://www.ncbi.nlm.nih.gov/pubmed/36590797
http://dx.doi.org/10.3389/fvets.2022.1055231
_version_ 1784860100060512256
author Pavlica, Matic
Kržan, Mojca
Nemec, Ana
Kosjek, Tina
Baš, Anže
Seliškar, Alenka
author_facet Pavlica, Matic
Kržan, Mojca
Nemec, Ana
Kosjek, Tina
Baš, Anže
Seliškar, Alenka
author_sort Pavlica, Matic
collection PubMed
description INTRODUCTION: Data are lacking on the pharmacokinetic profile and safety of levobupivacaine (LB) used for regional anesthesia of the maxilla and mandibles in dogs. METHODS: Infraorbital block (n = 10), inferior alveolar block (n = 10) or both infraorbital and inferior alveolar blocks (n = 10) were administered to dogs undergoing dental surgery under isoflurane anesthesia. The dose of LB was calculated as 0.11 ml/kg(2/3) for the infraorbital block and 0.18 ml/kg(2/3) for the inferior alveolar block. Blood samples were collected before and immediately after administration of the oral blocks, and 3, 4, 7, 12, 17, 32, 47, 62, 92, and 122 min thereafter. Quantification of LB in plasma was performed by LC-MS/MS. RESULTS AND DISCUSSION: The results are presented as median and interquartile range. In dogs in which all four quadrants of the oral cavity were desensitized with LB, the C(max) was 1,335 (1,030–1,929) ng/ml, the T(max) was 7 (4–9.5) min, and the AUC((0 → 120)) was 57,976 (44,954–96,224) ng min/ml. Plasma concentrations of LB were several times lower than the reported toxic concentrations, and no signs of cardiovascular depression or neurotoxicity were observed in any of the dogs, suggesting that the occurrence of severe adverse effects after administration of LB at the doses used in this study is unlikely.
format Online
Article
Text
id pubmed-9794753
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97947532022-12-29 The pharmacokinetics of levobupivacaine 0.5% after infraorbital or inferior alveolar block in anesthetized dogs Pavlica, Matic Kržan, Mojca Nemec, Ana Kosjek, Tina Baš, Anže Seliškar, Alenka Front Vet Sci Veterinary Science INTRODUCTION: Data are lacking on the pharmacokinetic profile and safety of levobupivacaine (LB) used for regional anesthesia of the maxilla and mandibles in dogs. METHODS: Infraorbital block (n = 10), inferior alveolar block (n = 10) or both infraorbital and inferior alveolar blocks (n = 10) were administered to dogs undergoing dental surgery under isoflurane anesthesia. The dose of LB was calculated as 0.11 ml/kg(2/3) for the infraorbital block and 0.18 ml/kg(2/3) for the inferior alveolar block. Blood samples were collected before and immediately after administration of the oral blocks, and 3, 4, 7, 12, 17, 32, 47, 62, 92, and 122 min thereafter. Quantification of LB in plasma was performed by LC-MS/MS. RESULTS AND DISCUSSION: The results are presented as median and interquartile range. In dogs in which all four quadrants of the oral cavity were desensitized with LB, the C(max) was 1,335 (1,030–1,929) ng/ml, the T(max) was 7 (4–9.5) min, and the AUC((0 → 120)) was 57,976 (44,954–96,224) ng min/ml. Plasma concentrations of LB were several times lower than the reported toxic concentrations, and no signs of cardiovascular depression or neurotoxicity were observed in any of the dogs, suggesting that the occurrence of severe adverse effects after administration of LB at the doses used in this study is unlikely. Frontiers Media S.A. 2022-12-14 /pmc/articles/PMC9794753/ /pubmed/36590797 http://dx.doi.org/10.3389/fvets.2022.1055231 Text en Copyright © 2022 Pavlica, Kržan, Nemec, Kosjek, Baš and Seliškar. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Veterinary Science
Pavlica, Matic
Kržan, Mojca
Nemec, Ana
Kosjek, Tina
Baš, Anže
Seliškar, Alenka
The pharmacokinetics of levobupivacaine 0.5% after infraorbital or inferior alveolar block in anesthetized dogs
title The pharmacokinetics of levobupivacaine 0.5% after infraorbital or inferior alveolar block in anesthetized dogs
title_full The pharmacokinetics of levobupivacaine 0.5% after infraorbital or inferior alveolar block in anesthetized dogs
title_fullStr The pharmacokinetics of levobupivacaine 0.5% after infraorbital or inferior alveolar block in anesthetized dogs
title_full_unstemmed The pharmacokinetics of levobupivacaine 0.5% after infraorbital or inferior alveolar block in anesthetized dogs
title_short The pharmacokinetics of levobupivacaine 0.5% after infraorbital or inferior alveolar block in anesthetized dogs
title_sort pharmacokinetics of levobupivacaine 0.5% after infraorbital or inferior alveolar block in anesthetized dogs
topic Veterinary Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794753/
https://www.ncbi.nlm.nih.gov/pubmed/36590797
http://dx.doi.org/10.3389/fvets.2022.1055231
work_keys_str_mv AT pavlicamatic thepharmacokineticsoflevobupivacaine05afterinfraorbitalorinferioralveolarblockinanesthetizeddogs
AT krzanmojca thepharmacokineticsoflevobupivacaine05afterinfraorbitalorinferioralveolarblockinanesthetizeddogs
AT nemecana thepharmacokineticsoflevobupivacaine05afterinfraorbitalorinferioralveolarblockinanesthetizeddogs
AT kosjektina thepharmacokineticsoflevobupivacaine05afterinfraorbitalorinferioralveolarblockinanesthetizeddogs
AT basanze thepharmacokineticsoflevobupivacaine05afterinfraorbitalorinferioralveolarblockinanesthetizeddogs
AT seliskaralenka thepharmacokineticsoflevobupivacaine05afterinfraorbitalorinferioralveolarblockinanesthetizeddogs
AT pavlicamatic pharmacokineticsoflevobupivacaine05afterinfraorbitalorinferioralveolarblockinanesthetizeddogs
AT krzanmojca pharmacokineticsoflevobupivacaine05afterinfraorbitalorinferioralveolarblockinanesthetizeddogs
AT nemecana pharmacokineticsoflevobupivacaine05afterinfraorbitalorinferioralveolarblockinanesthetizeddogs
AT kosjektina pharmacokineticsoflevobupivacaine05afterinfraorbitalorinferioralveolarblockinanesthetizeddogs
AT basanze pharmacokineticsoflevobupivacaine05afterinfraorbitalorinferioralveolarblockinanesthetizeddogs
AT seliskaralenka pharmacokineticsoflevobupivacaine05afterinfraorbitalorinferioralveolarblockinanesthetizeddogs